Identification of a minimal region of loss on chromosome 6q27 associated with poor survival of high-risk neuroblastoma patients.


Journal

Cancer biology & therapy
ISSN: 1555-8576
Titre abrégé: Cancer Biol Ther
Pays: United States
ID NLM: 101137842

Informations de publication

Date de publication:
03 05 2020
Historique:
pubmed: 22 1 2020
medline: 17 12 2020
entrez: 22 1 2020
Statut: ppublish

Résumé

Patients with high-risk neuroblastoma (HR-NB) often initially respond to therapy, but afterward they become resistant and disease recurred. Unfortunately, it does not exist one or more specific chromosome defects associated with relapse or refractory NB. Recently, genomic evidence from primary tumors indicated that the distal region of chromosome 6q is loss in HR-NB patients with fatal outcome. We identified a minimal common region of loss of chromosome 6q27 spanning an area of 2.09 Mb by high-resolution DNA copy number data of a small cohort of HR-NB samples carrying 6q loss. This region of loss harbored five genes

Identifiants

pubmed: 31959052
doi: 10.1080/15384047.2019.1704122
pmc: PMC7515498
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

391-399

Références

J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093
pubmed: 29514301
Pediatr Clin North Am. 2015 Feb;62(1):225-56
pubmed: 25435121
Nat Genet. 2013 Jan;45(1):12-7
pubmed: 23202128
Genomics. 1997 Jun 1;42(2):342-4
pubmed: 9192857
Nat Rev Cancer. 2013 Jun;13(6):397-411
pubmed: 23702928
Pediatr Blood Cancer. 2011 Apr;56(4):578-83
pubmed: 21298742
JAMA. 2012 Mar 14;307(10):1062-71
pubmed: 22416102
N Engl J Med. 2005 Nov 24;353(21):2243-53
pubmed: 16306521
Oncotarget. 2017 May 30;8(32):53194-53209
pubmed: 28881804
J Clin Oncol. 2017 Aug 1;35(22):2580-2587
pubmed: 28471719
Blood. 2004 Jan 1;103(1):309-12
pubmed: 12969958
Cell Tissue Res. 2018 May;372(2):195-209
pubmed: 29572647
N Engl J Med. 1999 Jun 24;340(25):1954-61
pubmed: 10379019
Genes Chromosomes Cancer. 2007 Oct;46(10):936-49
pubmed: 17647283
Nature. 2003 Oct 23;425(6960):805-11
pubmed: 14574404
J Clin Oncol. 2009 Jan 10;27(2):289-97
pubmed: 19047291
Oncogene. 2007 Feb 1;26(5):683-700
pubmed: 16878154
J Clin Oncol. 2009 Mar 1;27(7):1026-33
pubmed: 19171713
J Clin Oncol. 2008 Mar 20;26(9):1504-10
pubmed: 18349403
Nat Genet. 2013 Mar;45(3):279-84
pubmed: 23334666
Annu Rev Med. 2015;66:49-63
pubmed: 25386934
Nature. 2012 Feb 22;483(7391):589-93
pubmed: 22367537
N Engl J Med. 1996 Jan 25;334(4):225-30
pubmed: 8531999
J Clin Oncol. 2010 Jul 20;28(21):3516-24
pubmed: 20567002
Pediatr Blood Cancer. 2019 Apr;66(4):e27556
pubmed: 30479064
J Mol Biol. 2006 Jun 16;359(4):863-75
pubmed: 16690081
Oncotarget. 2018 May 25;9(40):25903-25921
pubmed: 29899830
J Clin Oncol. 2005 Apr 1;23(10):2280-99
pubmed: 15800319
Pediatr Blood Cancer. 2019 May;66(5):e27635
pubmed: 30688024
N Engl J Med. 2010 Jun 10;362(23):2202-11
pubmed: 20558371

Auteurs

Marzia Ognibene (M)

Laboratorio Cellule Staminali Post Natali e Terapie Cellulari, IRCCS Istituto Gaslini, Genova, Italy.

Martina Morini (M)

Laboratorio di Biologia Molecolare, IRCCS Istituto Gaslini, Genova, Italy.

Alberto Garaventa (A)

Dipartimento di Emato-oncologia, IRCCS Istituto Gaslini, Genova, Italy.

Marina Podestà (M)

Laboratorio Cellule Staminali Post Natali e Terapie Cellulari, IRCCS Istituto Gaslini, Genova, Italy.

Annalisa Pezzolo (A)

Laboratorio Cellule Staminali Post Natali e Terapie Cellulari, IRCCS Istituto Gaslini, Genova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH